Amplia Therapeutics Ltd (ASX:ATX) CEO and managing director Dr John Lambert has tendered his resignation, effective November 2022, in order to facilitate a change of executive leadership and seek new challenges.
Dr Lambert will leave the company in November but is expected to remain available to assist with an orderly transition of the role.
“It has been a great privilege to serve as CEO of Amplia for the last few years and I am incredibly proud to have overseen the growth of Amplia over that time,” outgoing CEO and MD Dr Lambert said.
“I am pleased to have built an outstanding team with the resources to progress the pipeline to significant value inflexions.
“There are even more exciting times ahead for Amplia but I feel that it is an appropriate time for an executive leadership transition and for me to seek new challenges.
“I have enjoyed exceptional support from the board and I thank them for their guidance and oversight during my time as CEO.”
Taking Amplia to next stage
Amplia will begin the search for a new CEO will begin immediately in order to facilitate a smooth transition without interruption to the company’s operations.
“The Amplia board would like to thank John for his contributions to Amplia over the last four years and we wish him well with the next stage of his career,” Amplia Therapeutics chair Dr Warwick Tong said.
“John has successfully led Amplia through the major and important transition from a pre-clinical stage company to one with clinical stage programs.
“Our lead asset, AMP945, recently started a Phase 2 clinical trial in patients with pancreatic cancer and a second Phase 2 trial in pulmonary fibrosis is in advanced preparation.
“We will be seeking to identify a new CEO with the ability to build on the established clinical development capability and to take the company to its next stage.”